SCHEMBL30714634

SCHEMBL30714634

Cc1ncc(COc2ccc3nn(C)c(C(=O)N[C@H](C(N)=O)[C@@H](C)O)c3c2)s1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.34
MCHR1 Q99705 2/20 0.33
RAB9A P51151 4/20 0.32
NPC1 O15118 3/20 0.32
SCN9A Q15858 1/20 0.32
ENPP2 Q13822 1/20 0.32
POLB P06746 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CNR1 P21554 3/20 0.31
CNR2 P34972 1/20 0.31
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
MAPK1 P28482 1/20 0.30
CASP1 P29466 1/20 0.30
CASP7 P55210 1/20 0.30
HSD17B10 Q99714 1/20 0.30
PDE10A Q9Y233 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714669 0.91 HPGDS (0.38) KMT2AMCHR1RAB9ANPC1SCN9A
SCHEMBL30714744 0.91 HPGDS (0.38) KMT2AMCHR1RAB9ANPC1SCN9A
SCHEMBL30714632 0.87 KMT2A (0.33) KMT2AMCHR1RAB9ANPC1SCN9A
SCHEMBL30714602 0.85 NPC1 (0.35) KMT2ARAB9ANPC1SCN9AENPP2
SCHEMBL26874831 0.82 MCHR1 (0.38) KMT2AMCHR1RAB9APOLBL3MBTL1
SCHEMBL30714604 0.82 MCHR1 (0.37) KMT2AMCHR1RAB9ANPC1POLB
SCHEMBL26696031 0.81 MCHR1 (0.37) KMT2AMCHR1RAB9ANPC1POLB
SCHEMBL30714646 0.81 MCHR1 (0.36) KMT2AMCHR1RAB9ANPC1SCN9A
SCHEMBL30714637 0.80 ACACB (0.42) CNR2
SCHEMBL30714670 0.80 MCHR1 (0.40) KMT2AMCHR1RAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 KMT2A 3017/4885MCHR1 1891/4885RAB9A 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.